Company Encyclopedia
View More
name
CQP
000950.SZ
C.Q. Pharmaceutical Holding Co., Ltd. engages in the wholesale and retail of medicines and medical devices. The company is involved in the pharmaceutical commerce, warehousing logistics, pharmaceutical industry, and research and development businesses.
402.16 B
000950.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking10/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE3.26%C
    • Profit Margin0.45%C
    • Gross Margin7.08%E
  • Growth ScoreC
    • Revenue YoY4.23%C
    • Net Profit YoY-6.13%C
    • Total Assets YoY1.66%C
    • Net Assets YoY5.71%B
  • Cash ScoreB
    • Cash Flow Margin22167.84%A
    • OCF YoY4.23%C
  • Operating ScoreA
    • Turnover1.24A
  • Debt ScoreE
    • Gearing Ratio75.67%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CQP: As of the end of October, a total of RMB 80.9988 million has been spent to repurchase shares

    CQP announced that the company plans to repurchase shares in July 2025, with a total funding amount of 80 million to 100 million yuan, and the repurchase price not exceeding 6.6 yuan per share, with a duration of 12 months. As of October 31, the company has cumulatively repurchased 15.4066 million shares, accounting for 0.8915% of the total share capital, with a highest transaction price of 5.48 yuan per share and a lowest of 5.01 yuan per share, totaling a payment amount of 80.9988 million yuan. The company will continue to implement the repurchase according to the plan and disclose information in a timely manner

    Zhitong·
    SZ
    000950
    -0.18%
    Zhitong·
    SZ
    000950
    -0.18%

    General Technology CQP signs strategic cooperation agreement with Johnson & Johnson Innovation Pharmaceuticals

    On October 31, General Technology CQP signed a strategic cooperation agreement with Johnson & Johnson Innovation Pharmaceuticals. According to the agreement, both parties will fully leverage their platform resources and professional technical advantages, focusing on key aspects of controlled substances channel management, and collaboratively promote the channel management of controlled substances towards higher standards, stricter regulations, and better efficiency, jointly creating a controlled substances supply chain system that is patient-centered while ensuring drug accessibility and safety

    Zhitong·
    SZ
    000950
    -0.18%
    Zhitong·
    SZ
    000950
    -0.18%

    CQP: In the third quarter, the net profit attributable to the parent company was 102 million yuan, an increase of 87.94% year-on-year

    On October 27th, CQP announced that in the third quarter of 2025, it achieved operating revenue of 21.023 billion yuan, a year-on-year increase of 5.57%; the net profit attributable to shareholders of the listed company was 102 million yuan, a year-on-year increase of 87.94%; basic earnings per share were 0.06 yuan. In the first three quarters, it achieved operating revenue of 62.211 billion yuan, a year-on-year increase of 4.22%; the net profit attributable to shareholders of the listed company was 384 million yuan, a year-on-year increase of 31.41%

    Zhitong·
    SZ
    000950
    -0.18%
    Zhitong·
    SZ
    000950
    -0.18%

    CQP: It is expected that the net profit for the first three quarters will increase by 22.51%-36.88% year-on-year

    CQP expects its net profit for the first three quarters of 2025 to be 358 million yuan, a year-on-year increase of 22.51%-36.88%. The net profit after deducting non-recurring gains and losses is expected to be 348 million yuan, a year-on-year increase of 25.48%-40.62%. The basic earnings per share are expected to be 0.2 yuan/share. The company's various businesses continue to develop, with steady growth in operating revenue

    Zhitong·
    SZ
    000950
    -0.18%
    Zhitong·
    SZ
    000950
    -0.18%

    CQP: The clinical trial for hydrochloride prasugrel tablets has been approved

    CQP announced that its holding subsidiary Chongqing Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for Prasugrel Hydrochloride Tablets. This medication is used to prevent cardiovascular diseases such as acute coronary syndrome and is currently marketed in over 70 countries worldwide, but has not yet been launched in China

    Zhitong·
    SZ
    000950
    -0.18%
    Zhitong·
    SZ
    000950
    -0.18%
    © 2025 Longbridge｜Disclaimer